AKASA vs Waystar
Best of breed AI against an incumbent network, and the AI centrality split is the whole story: AKASA graded A because the models are the product, Waystar C because AltitudeAI accelerates a clearinghouse that would sell without it. AKASA is one genuinely model driven engine across the revenue cycle, trained on payer and EHR behaviour so it survives the portal changes that break scripted automation, sold to a reported 650 hospitals. Waystar is scale itself, a network of roughly one million providers processing six billion transactions a year, which is a genuine data advantage its predictive denial tools draw on, and its AI may already be inside the platform a buyer runs. Oversight favours AKASA modestly, expert in the loop at B against Waystar's autonomously generated appeals at C. If your failure mode is wanting the most genuinely model driven automation across the cycle, start with AKASA, confirming integration depth off Epic. If your failure mode is wanting AI inside the network you already run, start with Waystar.
- Genuinely model driven rather than a bundled layer: models trained on payer portal, EHR, and clearinghouse behaviour that tolerate interface change, graded A on AI centrality where Waystar's AltitudeAI accelerates a platform bought for other reasons, graded C.
- One engine across the cycle: coding, documentation integrity, prior authorization, and claims in a single platform graded A on setting coverage, with an expert in the loop design that escalates edge cases.
- Enterprise scale with a flagship reference: more than 650 hospitals and 6,500 outpatient facilities, a reported 43 million training documents, and a Cleveland Clinic collaboration.
- Network scale is the asset: a reported six billion transactions annually for roughly one million providers, touching about half of US patients, graded A on interoperability, a data advantage that feeds its predictive denial scoring.
- The AI may already be in the platform you run: AltitudeCreate drafts appeals from more than 1,100 payer specific templates, AltitudePredict prioritises denials by expected cash value, AltitudeAssist compresses denial prevention to minutes.
- A broad certification set spanning HIPAA, HITRUST, SOC 2, and PCI DSS, graded B on security certifications, where AKASA publishes none located.
Side-by-Side
| Axis | A AKASA |
W Waystar |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | — |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage | — |
Both are partially assessed on this index, roughly six graded axes each, and the contrast is best of breed AI against incumbent bundle. AKASA grades A on AI centrality because the models are the product and genuinely tolerate portal change; Waystar grades C because the revenue cycle platform is what gets bought and the AI rides on top. On oversight, AKASA states an expert in the loop design but does not publish its confidence threshold, graded B, while Waystar autonomously generates appeal letters with no published review step, graded C. AKASA's EHR depth is uneven off Epic, a diligence item for Cerner and MEDITECH sites. Waystar's scale is a real model advantage, not just marketing reach. A buyer should establish whether Waystar's AltitudeAI is bundled or priced separately. Neither publishes pricing.